Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

IL-38 serum levels in patients with Behcet’s disease and the relationship with clinical features

  • 4 Accesses

Abstract

Behcet’s disease (BD) is a chronic multisystem autoimmune disorder. Various cytokines take part in the pathogenesis of this disease. Interleukin (IL)-38, a new member of IL-1 cytokine family, has been reported to have antiinflammatory properties; however, its role in BD has not been investigated yet. In this study, we aimed to examine the probable role of IL-38 in the clinical context of BD. A total of 81 patients with BD and 81 age- and sex-matched healthy subjects as controls were included in this study. The serum levels of IL-38 were measured in patients and controls sera using enzyme-linked immunosorbent assay. The relationship between the serum levels of IL-38 and clinical and laboratory characteristics of the patients were determined. IL-38 serum levels were significantly lower in patients in comparison with healthy controls at P = 0.003. We found significant differences between IL-38 levels in BD patients with positive and negative pathergy tests (P = 0.048) and patients with and without eye involvement (P = 0.046). Despite the absence of significant differences in serum levels between male and female patients, IL-38 levels were higher in female patients with a positive pathergy test (P = 0.048) and those patients with eye involvement (P = 0.046). As healthy controls showed higher IL-38 serum levels than patients, a protective anti-inflammatory role of IL-38 in BD is suggested. Together, these results suggest that the positive relationship between IL-38 serum levels and eye involvement that IL-38 may play a role in this clinical feature of the disease.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Tong B, Liu X, Xiao J, Su G. Immunopathogenesis of Behcet’s disease Frontiers Immunol 2019; 10: 665.

  2. 2.

    Davcakir N, Dervis E, Benian O, et al. Prevalence of Behcet’s disease in rural western Turkey: a preliminary report. Clin Exp Rheumatol 2004; 22: S53–5.

  3. 3.

    Galeone M, Colucci R, D’Erme AM, Moretti S, Lotti T. Potential infectious etiology of Behçet’s disease. Patholog Res Int 2012; 2012: 595380.

  4. 4.

    Mashall SE. Behcet’s disease. Best Pract Res Clin Rheumatol 2004; 18: 291.

  5. 5.

    Takeuchi M, Kastner DL, Remmers EF. The immunogenetics of Behçet’s disease: a comprehensive review. J Autoimmun 2015; 64: 137.

  6. 6.

    de Chambrun MP, Wechsler B, Geri G, Cacoub P, Saadoun D. Remmers New insights into the pathogenesis of Behcet’s disease. Autoimmunity Rev 2012; 11: 687.

  7. 7.

    Koarada S, Haruta Y, Tada Y, et al. Remmers Increased entry of CD4+ T cells into the Th1 cytokine effector pathway during T-cell division following stimulation in Behcet’s disease. Rheumatology 2004; 43: 843.

  8. 8.

    Ben Ahmed M, Houman H, Miled M, Dellagi K, Louzir H. Remmers Involvement of chemokines and Thl cytokines in the pathogenesis of mucocutaneous lesions of Behcet’s disease. Arthritis Rheumatol 2004; 50: 2291.

  9. 9.

    Gholijani N, Ataollahi MR, Samiei A, Aflaki E, Shenavandeh S, Kamali-Sarvestani E. An elevated pro-inflammatory cytokines profile in Behcet’s disease: a multiplex analysis. Immunol Lett 2017; 186: 46.

  10. 10.

    Nanke Y, Yago T, Kotake S. The role of Thl7 cells in the pathogenesis of Behcet’s disease. J Clin Med 2017; 6: 74.

  11. 11.

    Aktas Cetin E, Cosan F, Cene A, Deniz G Deniz IL-22-secreting Th22 and IFN-γ-secreting Th17 cells in Behçet’s disease. Modern Rheumatol 2014; 24: 802.

  12. 12.

    Shimizu J, Takai K, Fujiwara N, et al. Deniz Excessive CD4+ T cells co-expressing interleukin-17 and interferon-γ in patients with Behçet’s disease. Clin Exp Immunol 2012; 168: 68.

  13. 13.

    Direskeneli H, Fujita H, Akdis CA. Akdis Regulation of TH17 and regulatory T cells in patients with Behcet disease. J Allergy Clin Immunol 2011; 128: 665.

  14. 14.

    Lin H, Ho AS, Haley-Vicente D, et al. Akdis Cloning and characterization of IL-1HY2, a novel interleukin-1 family member. J Biol Chem 2001; 276: 20597.

  15. 15.

    Nicklin MJH, Barton JL, Nguyen M, FitzGerald MG, Duff GW, Kornman K. Akdis A sequence-based map of the nine genes of the human interleukin-1 cluster. Genomics 2002; 79: 718.

  16. 16.

    Bensen JT, Dawson PA, Mychaleckyj JC, Bowden DW. Identification of a novel human cytokine gene in the interleukin gene cluster on chromosome 2ql2-14. J Interferon Cytokine Res 2001; 21: 899.

  17. 17.

    Gabay C, Towne JE. Regulation and function of interleukin-36 cytokines in homeostasis and pathological conditions. J Leuk Biol 2015; 97: 645.

  18. 18.

    Hahn M, Frey S, Hueber AJ. The novel interleukin-1 cytokine family members in inflammatory diseases. Curr Opin Rheumatol 2017; 29: 208.

  19. 19.

    Jung MY, Kang SW, Kim SK, et al. The interleukin-1 family gene polymorphisms in Korean patients with rheumatoid arthritis. Scand J Rheumatol 2010; 39: 190.

  20. 20.

    Rahman P, Sun S, Peddle L, Snelgrove T, Melay W, Greenwood C, et al. Association between the interleukin-1 family gene cluster and psoriatic arthritis. Arthritis Rheumatol 2006; 54: 2321.

  21. 21.

    Guo ZS, Li C, Lin ZM, et al. Association of IL-1 gene complex members with ankylosing spondylitis in Chinese Han population. Int J Immunogenet 2010; 37: 33.

  22. 22.

    Dehghan A, Dupuis J, Barbalic M, et al. Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation 2011; 123: 731.

  23. 23.

    Wang M, Wang B, Ma Z, et al. Detection of the novel IL-1 family cytokines by QAH-IL1F-1 assay in rheumatoid arthritis. Cell Mol Biol 2016; 62: 31.

  24. 24.

    Rudloff I, Godsell J, Nold-Petry CA, et al. Brief Report: interleukin-38 exerts anti-inflammatory functions and is associated with disease activity in systemic lupus erythematosus. Arthritis Rheumatol 2015; 67: 3219.

  25. 25.

    Wang H-J, Jiang Y-F, Wang X-R, Zhang M-L, Gao P-J. Elevated serum interleukin-38 level at baseline predicts virological response in telbivudine-treated patients with chronic hepatitis B. World J Gastroenterol 2016; 22: 4529.

  26. 26.

    Zhong Y, Yu K, Wang X, Wang X, Ji Q, Zeng Q. Elevated plasma IL-38 concentrations in patients with acute ST-segment elevation myocardial infarction and their dynamics after reperfusion treatment. Mediators Inflamm 2015; 2015: 490120.

  27. 27.

    Chu M, Chu I, Yung E, et al. Aberrant expression of novel cytokine IL-38 and regulatory T lymphocytes in childhood asthma. Molecules 2016; 21: 933.

  28. 28.

    Takenaka S, Kaieda S, Kawayama T, et al. IL-38: a new factor in rheumatoid arthritis. Biochem Biophy Rep 2015; 4: 386.

  29. 29.

    Boutet MA, Bart G, Penhoat M, et al. Distinct expression of interleukin (IL)-36alpha, beta and gamma, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn’s disease. Clin Exp Immunol 2016; 184: 159.

  30. 30.

    Yazici H, Yazici Y. Criteria for Behçet’s disease with reflections on all disease criteria. J Autoimmunity 2014; 48: 104.

  31. 31.

    International Team for the Revision of the International Criteria for Behçet’s Disease (ITR-ICBD). The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 2014; 28: 338.

  32. 32.

    van de Veerdonk FL, Stoeckman AK, Wu G, et al. IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proc Natl Acad Sci USA 2012; 109: 3001.

  33. 33.

    Cozzani E, Drosera M, Gasparini GA-O, Parodi A. Serology of lupus erythematosus: correlation between immunopathological features and clinical aspects. Autoimmune Dis 2014; 2014: 321359.

  34. 34.

    Nowatzky J, Chajek-Shaul T. Biomarkers in Behcet’s disease: diagnosis and disease activity. Int J Clin Rheum 2009; 4: 271.

  35. 35.

    Türsen Ü. Pathophysiology of the Behcet’s disease. Pathol Res Int 2012; 2012: 493015.

  36. 36.

    Shimizu J, Yoshikawa H, Takada E, Hirotsu C, Suzuki N. Unbalanced helper T cell function in Behcet’s disease. Inflamm Regen 2011; 31: 296.

  37. 37.

    Hamzaoui K. Th17 cells in Behcet’s disease: a new immunoreg-ulatory axis. Clin Exp Rheumatol 2011; 29: 71.

  38. 38.

    Davatchi F, Chams-Davatchi C, Ghodsi Z, et al. Diagnostic value of pathergy test in Behcet’s disease according to the change of incidence over the time. Clin Rheumatol 2011; 30: 1151.

  39. 39.

    Belguendouz H, Messaoudène D, Lahmar K, et al. Interferon-γ and nitric oxide production during Behçet uveitis: immunomodulatory effect of interleukin-10. J Interferon Cytokine Res 2011; 31: 643.

  40. 40.

    Park UC, Kim TW, Yu HG. Immunopathogenesis of ocular Behçet’s disease. J Immunol Res 2014; 2014: 653539.

  41. 41.

    Yu HG, Lee DS, Seo JM, et al. The number of CD8+ T cells and NKT cells increases in the aqueous humor of patients with Behçet’s uveitis. Clin Exp Immunol 2004; 137: 437.

  42. 42.

    Belguendouz H, Messaoudene D, Hartani D, et al. Effect of corticotherapy on interleukin-8 and -12 and nitric oxide production during Behçet and idiopathic uveitis. J Fr Ophtalmol 2008; 31: 387.

  43. 43.

    Mora J, Schlemmer A, Wittig I, et al. Interleukin-38 is released from apoptotic cells to limit inflammatory macrophage responses. J Mol Cell Biol 2016; 8: 426.

  44. 44.

    Shenavandeh S, Jahanshahi KA, Aflaki E, Tavassoli A. Frequency of HLA-B5, HLA-B51 and HLA-B27 in patients with idiopathic uveitis and Behçet’s disease: a case-control study. Reumatologia 2018; 56: 67.

Download references

Acknowledgement

Research reported in this publication was supported by Elite Researcher Grant Committee under award number [971223] from the National Institute for Medical Research Development (NIMAD), Tehran, Iran.

Author information

Correspondence to Zahra Amirghofran.

Additional information

Conflicts of Interest

The authors declare no conflicts of interest.

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zarrabi, M., Gholijani, N., Shenavandeh, S. et al. IL-38 serum levels in patients with Behcet’s disease and the relationship with clinical features. Eur Cytokine Netw 30, 82–87 (2019). https://doi.org/10.1684/ecn.2019.0430

Download citation

Keywords

  • IL-38
  • Behcet’s disease
  • autoimmune disease
  • cytokine